Memixa (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at NMDA receptors. By blocking excessive calcium entry caused by prolonged glutamate stimulation, it limits excitotoxic neuronal injury while allowing normal synaptic activity needed for learning and memory.

The dose of Memixa is individualized by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Healthcare professionals determine the appropriate starting and maintenance doses according to clinical guidelines.

Safety data for memantine in pregnancy and lactation are limited. The medication should only be used if the potential benefit outweighs any possible risk, and the decision must be made in consultation with a qualified healthcare provider.

To request Memixa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for Alzheimer’s disease is the acetylcholinesterase inhibitor class (e.g., donepezil). While acetylcholinesterase inhibitors increase cholinergic activity, memantine modulates glutamatergic signaling. Both classes may be used together for additive benefit, but they have distinct mechanisms, side‑effect profiles and dosing considerations.

Memixa should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Memixa is taken orally, usually as a tablet. Patients should swallow the tablet whole with a glass of water, preferably at the same time each day, unless directed otherwise by their prescriber.

Serious adverse events include seizures, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and emergent suicidal thoughts or behavior. Any of these symptoms require immediate medical attention.

Memixa is contraindicated in patients with known hypersensitivity to memantine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled cardiovascular disease, or a history of seizures, and it should be avoided unless a healthcare professional determines the benefits outweigh the risks.